Knowthestock.com
ARMP - Armata Pharmaceuticals Inc

Sell

Weak GrowthStock Price Very High

20%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 987.61%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -475.22%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.7
Debt Ratio is 0.44
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Armata Pharmaceuticals Inc (ARMP) - www.armatapharma.com
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United Statesand Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Exchange - NYSE MKT LLC
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Todd Patrick
Employees - 61
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.